Download biomedica product listVascular Endothelial Growth Factor (VEGF) induces angiogenesis, but also disrupts vascular barrier function in diseased tissues. VEGF-mediated pathogenic effects are due to its effects on vascular permeability, resulting in injury to ischemic tissues after stroke or myocardial infarction. In cancer, VEGF-mediated disruption of the vascular barrier may lead to metastatic disease.
Check out our new high quality human VEGF ELISA – developed and manufactured by Biomedica:
Highlights:
√ SMALL SAMPLE VOLUME: only 10µl sample / well required
√ HIGH SENSITIVITY: measurable values in both serum and plasma
√ RELIABLE: rigorously validated according to FDA/ICH/EMEA guidelines
√ EASY: ready to use calibrators & controls included
√ EXCELLENT: correlates with existing methods
√ DAY TEST: results in 4.5 h
Literature:
Review: VEGF in Signaling and Disease: Beyond Discovery and Development. Apte RS et al., Cell. 2019; 176, 6: 1248–64.
e-Poster: “Highly sensitive quantification of human VEGF with an ELISA”